SCHEMBL9920993

SCHEMBL9920993

CC(C)(C)CN/C(=N/C(=O)c1ccc(Cl)cc1)Nc1cc(C(F)F)[nH]n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAB2 O43741 6/20 0.41
PRKAG1 P54619 6/20 0.41
PRKAA2 P54646 6/20 0.41
PRKAA1 Q13131 6/20 0.41
PRKAG3 Q9UGI9 6/20 0.41
PRKAG2 Q9UGJ0 6/20 0.41
PRKAB1 Q9Y478 6/20 0.41
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
CCNA2 P20248 2/20 0.38
CDK2 P24941 2/20 0.38
CCNA1 P78396 2/20 0.38
MAPT P10636 2/20 0.38
NR1I2 O75469 1/20 0.38
AHR P35869 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9920898 0.89 PRKAB2 (0.39) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL9920991 0.89 PRKAB2 (0.41) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL9921068 0.87 PRKAB2 (0.51) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL19360246 0.85 STK25 (0.39) NPC1RAB9ACCNA2CDK2CCNA1
SCHEMBL9921050 0.84 CCNA2 (0.43) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL9921103 0.81 MAPK1 (0.42) NPC1RAB9AMAPTSMN1; SMN2ALOX15
SCHEMBL9920708 0.80 STK25 (0.36) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL9921007 0.79 STK25 (0.45) NPC1RAB9ACCNA2CDK2CCNA1
SCHEMBL9921056 0.78 CYP2D6 (0.40) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL9920875 0.78 RAB9A (0.35) NPC1RAB9ACCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2648511-B1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORP (US) 2017-06-28 EP disclosed
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed
US-9139532-B2 Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-09-22 US disclosed
US-9139532-B2 Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-09-22 US disclosed
WO-2012078874-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed